terfenadine has been researched along with quinidine in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.67) | 18.2507 |
| 2000's | 20 (44.44) | 29.6817 |
| 2010's | 18 (40.00) | 24.3611 |
| 2020's | 4 (8.89) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Keserü, GM | 1 |
| Bechstedt, S; Gessner, G; Heinemann, SH; Schönherr, R; Zacharias, M | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Jia, L; Sun, H | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, CH; De Clercq, E; Feng, D; Ginex, T; Kang, D; Lee, KH; Liu, X; Luque, FJ; Murugan, NA; Pannecouque, C; Steitz, TA; Wang, Z; Wei, F; Wu, G; Yang, Y; Zhan, P; Zhang, H; Zhang, J; Zhao, T | 1 |
| Adebesin, AM; Falck, JR; Fischer, R; Konkel, A; Lossie, J; Paudyal, MP; Puli, N; Schunck, WH; Vijaykumar, J; Wesser, T; Westphal, C; Zhu, C | 1 |
| Abadi, AH; Abdel-Halim, M; Engel, M; Fathalla, RK; Hammam, MA; Hartmann, RW; Hefnawy, A; Keeton, AB; Maher, A; Maxuitenko, Y; Piazza, GA; Racheed, NAS; Sigler, S | 1 |
| Consoli, V; D'Agata, V; D'Amico, AG; Fallica, AN; Floresta, G; Intagliata, S; Pittalà, V; Rescifina, A; Romeo, G; Salerno, L; Sorrenti, V; Vanella, L | 1 |
| Darrow, WR; Woosley, R | 1 |
| Cuss, FM; Del Prado, M; Egan, RW; Hey, JA; Kreutner, W; Lin, CC; Sherwood, J | 1 |
| Hanada, E; Iga, T; Ohtani, H; Sawada, Y; Yamamoto, K | 1 |
| De Clerck, F; Lu, HR; Remeysen, P | 1 |
| Endoh, M; Ishii, K; Kimura, M; Kondo, K; Takahashi, M | 1 |
| Dong, DL; Du, ZM; Li, Z; Wang, HZ; Xu, CQ; Xu, DH; Yang, BF | 1 |
| Abe, J; Hamada, Y; Harada, T; Hashimoto, K; Horii, I; Sawada, Y; Shiotani, M | 1 |
| Roden, DM | 1 |
| Moss, AJ | 1 |
| Cox, BF; Gintant, GA; Limberis, JT; Martin, RL; Su, Z | 1 |
| Kawabata, T; Kitamura, Y; Koto, H; Kusuhara, H; Matsuura, S; Sugiyama, Y; Tsuchiya, H; Tsujimoto, H | 1 |
| Chiba, M; Ishii, Y; Shibata, Y; Takahashi, H | 1 |
| Deshmukh, SV; Durston, J; Shomer, NH | 1 |
| Beale, KK; Bertino, JS; Ma, JD; Nafziger, AN; Trivedi, M; Tsunoda, SM | 1 |
| Kataoka, M; Masaoka, Y; Sakuma, S; Yamashita, S; Yokoyama, T | 1 |
| Dong, QX; Gao, JM; He, JH; Huang, CJ; Li, CQ; Xu, YQ; Xuan, YX; Yu, HP; Zhu, JJ | 1 |
| Badyra, B; Kudolo, J; Lisowski, B; Polak, S; Wiśniowska, B | 1 |
| Hinoi, E; Miyawaki, I; Tsubouchi, T; Watanabe, K; Yamada, T | 1 |
| Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N | 1 |
| Chang, H; Chen, C; Du, H; Guan, C; Li, C; Qiu, L; Wang, S; Wang, T; Wu, Y; Zhang, L; Zhang, S; Zhou, H | 1 |
2 review(s) available for terfenadine and quinidine
| Article | Year |
|---|---|
Long QT syndrome: reduced repolarization reserve and the genetic link.
Topics: Anti-Arrhythmia Agents; Disease Susceptibility; Female; Genotype; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male; Polymorphism, Genetic; Quinidine; Risk Factors; Terfenadine; Torsades de Pointes | 2006 |
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Digoxin; Drug Interactions; Genotype; Humans; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Prescription Drugs; Propanolamines; Quinidine; Reproducibility of Results; Terfenadine | 2010 |
43 other study(ies) available for terfenadine and quinidine
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents.
Topics: Amino Acid Sequence; Animals; Cells, Cultured; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Oocytes; Potassium Channels; Potassium Channels, Voltage-Gated; Quaternary Ammonium Compounds; Sequence Homology, Amino Acid; Xenopus laevis | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.
Topics: Animals; Anti-HIV Agents; Binding Sites; Cell Line, Tumor; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Molecular Dynamics Simulation; Molecular Structure; Pyrimidines; Rats, Wistar; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2019 |
Development of Robust 17(
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arachidonic Acids; Dose-Response Relationship, Drug; Drug Stability; Epoxide Hydrolases; Esterification; Hepatocytes; Humans; Male; Mice; Microsomes, Liver; Myocardial Infarction; Myocytes, Cardiac; Rats, Sprague-Dawley; Rats, Wistar | 2019 |
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Topics: Animals; Blood Proteins; Celecoxib; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Half-Life; Humans; Isoenzymes; Mice; Mice, Inbred C57BL; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Protein Binding; Pyrazoles; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2021 |
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
Topics: Acetamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Male; Molecular Docking Simulation; Molecular Structure; Protein Binding; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
Analysis of potential adverse drug reactions--a case of mistaken identity.
Topics: Astemizole; Atrial Fibrillation; Drug Interactions; Electrocardiography; Humans; Loratadine; Quinidine; Tachycardia, Ventricular; Terfenadine | 1994 |
Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs.
Topics: Animals; Cardiovascular System; Central Nervous System; Diphenhydramine; Electrocardiography; Electroencephalography; Guinea Pigs; Histamine H1 Antagonists; Hypnotics and Sedatives; Loratadine; Male; Promethazine; Quinidine; Terfenadine | 1995 |
Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Interactions; Electrocardiography; Electrophysiology; Histamine H1 Antagonists; Infusions, Intravenous; Male; Quinidine; Rats; Rats, Sprague-Dawley; Terfenadine | 1996 |
Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Anesthesia; Animals; Anti-Arrhythmia Agents; Blood Pressure; Delayed Rectifier Potassium Channels; Electrocardiography; Heart Rate; Male; Methoxamine; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quinidine; Rabbits; Terfenadine; Torsades de Pointes | 2000 |
An amino acid residue whose change by mutation affects drug binding to the HERG channel.
Topics: Amino Acid Sequence; Cation Transport Proteins; Ether-A-Go-Go Potassium Channels; Models, Molecular; Molecular Sequence Data; Mutagenesis; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation; Quinidine; Sequence Homology, Amino Acid; Terfenadine | 2001 |
Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Topics: Animals; Anti-Allergic Agents; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Ganglionic Stimulants; Ion Channel Gating; Mutation; Nicotine; Oocytes; Patch-Clamp Techniques; Phenethylamines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quinidine; Sulfonamides; Terfenadine; Xenopus laevis | 2004 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; Electrocardiography; Guinea Pigs; Haloperidol; Heart; Humans; Injections, Intravenous; Long QT Syndrome; Male; Nifedipine; Pimozide; Piperidines; Pyridines; Quinidine; Reproducibility of Results; Telemetry; Terfenadine; Thioridazine | 2005 |
Drug-induced QT prolongation: an update.
Topics: Electrocardiography; Fluoroquinolones; Humans; Long QT Syndrome; Quinidine; Terfenadine | 2006 |
Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Topics: Cell Line; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Kidney; Mesoridazine; Phenethylamines; Potassium; Potassium Channel Blockers; Quinidine; Sulfonamides; Terfenadine | 2006 |
Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Dogs; Female; Intestinal Absorption; Loperamide; Male; Mutation; Quinidine; Terfenadine | 2008 |
A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Topics: Area Under Curve; Cryopreservation; Cytochrome P-450 Enzyme System; Desipramine; Drug Interactions; Hepatocytes; Humans; Indinavir; Ketoconazole; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests; Quinidine; Technology, Pharmaceutical; Terfenadine | 2008 |
Validation of the use of nonnaive surgically catheterized rats for pharmacokinetics studies.
Topics: Animals; Antipyrine; Catheterization; Cost-Benefit Analysis; Femoral Artery; Hematocrit; Jugular Veins; Male; Pharmacokinetics; Quinidine; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Surgical Procedures, Operative; Terfenadine; Time Factors; Triazoles | 2008 |
Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Topics: Algorithms; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Erythromycin; Gene Expression; Glycerol; Humans; Intestinal Absorption; Loperamide; Models, Biological; Pharmaceutical Preparations; Propanolamines; Puromycin; Quinidine; Saquinavir; Solubility; Surface-Active Agents; Terfenadine; Verapamil; Vinblastine | 2011 |
Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Cardiotoxins; Clomipramine; Cyclophosphamide; Disease Models, Animal; Edema; Gentamicins; Heart Diseases; Heart Rate; Heart Ventricles; Larva; Microinjections; Nimodipine; Pericardium; Quinidine; Terfenadine; Tetracycline; Toxicity Tests; Verapamil; Yolk Sac; Zebrafish | 2014 |
How in vitro influences in silico utilized for the prediction of in vivo - pilot study of the drug-induced pro-arrhythmic potency prediction.
Topics: Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Dextromethorphan; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; In Vitro Techniques; Ketoconazole; Models, Cardiovascular; Patch-Clamp Techniques; Pilot Projects; Quinidine; Terfenadine | 2015 |
Telemetered common marmosets is useful for the assessment of electrocardiogram parameters changes induced by multiple cardiac ion channel inhibitors.
Topics: Animals; Astemizole; Body Temperature; Calcium Channel Blockers; Callithrix; Electrocardiography; Flecainide; Male; Models, Animal; Quinidine; Risk Assessment; Sotalol; Telemetry; Terfenadine; Verapamil; Voltage-Gated Sodium Channel Blockers | 2019 |
Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Topics: Acetamides; Albuterol; Animals; Carbamates; Chromatography, Liquid; Diazepam; Diclofenac; Digitoxin; Humans; Itraconazole; Ketoprofen; Liver; Metabolic Clearance Rate; Mice; Mice, Transgenic; Naproxen; Pharmaceutical Preparations; Phenytoin; Piperidines; Pravastatin; Pyrimidines; Quinidine; Tandem Mass Spectrometry; Telmisartan; Terfenadine; Verapamil | 2020 |
Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats.
Topics: Animals; Antipyrine; Atenolol; Carbamazepine; Cell Membrane; Digoxin; Diltiazem; Diphenhydramine; Drug Elimination Routes; Gabapentin; Lamotrigine; Liver; Memantine; Membrane Transport Proteins; Microdialysis; Muscle, Skeletal; Ofloxacin; Pharmaceutical Preparations; Propranolol; Pyrilamine; Quinidine; Rats; Terfenadine | 2021 |